Clinigen Group plc Clinigen Group Completes Acquisition of CSM (7553C)
October 02 2018 - 11:59AM
UK Regulatory
TIDMCLIN
RNS Number : 7553C
Clinigen Group plc
02 October 2018
2 October 2018
Clinigen Group plc
Clinigen Group Completes Acquisition of CSM
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the
global pharmaceutical and services company, today announces that it
has completed the acquisition of CSM Parent, Inc. ('CSM'), which
was announced on 27 September 2018 (the "Acquisition").
Following Admission of the Placing Shares on 1 October 2018
(details of the Placing having been announced by the Company on 27
September 2018 to coincide with the announcement of the
Acquisition), the Company now has in issue 131,949,754 ordinary
shares of 0.1p each, with voting rights. Clinigen does not hold any
shares in treasury. This figure of 131,949,754 ordinary shares may
be used by shareholders in Clinigen to determine if they are
required to notify their interest in, or a change in their interest
in, Clinigen under the Financial Conduct Authority's Disclosure and
Transparency Rules.
For further information, please contact:
Clinigen Group plc Tel:+44 (0) 1283 495 010
Shaun Chilton, Group Chief Executive
Martin Abell, Group Chief Financial
Officer
Matt Parrish, Head of Investor
Relations
Numis Securities Limited (Nominated Tel: +44 (0)20 7260 1000
Adviser, Joint Financial Adviser
and Joint Corporate Broker to
Clinigen)
Michael Meade
James Black
Freddie Barnfield
RBC Capital Markets (Joint Financial Tel: +44 (0)20 7653 4000
Adviser and Joint Corporate Broker
to Clinigen)
Marcus Jackson
Thomas Stockman
Elliot Thomas
Instinctif Partners (FPR Adviser Tel: +44 (0)20 7457 2020
to Clinigen)
Adrian Duffield
Melanie Toyne Sewell
Alex Shaw
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing ethical access to medicines. Its mission is to deliver
the right medicine to the right patient at the right time through
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines. Clinigen acquired Quantum Pharma in
November 2017.
For more information, please visit www.clinigengroup.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACQFKBDPPBDDFKK
(END) Dow Jones Newswires
October 02, 2018 11:59 ET (15:59 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024